$SXTPW
60 DEGREES PHARMACEUTICALS, INC.
CIK:0001946563|SEC Filings
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Income Statement [Abstract] | ||||||||
| Product Revenues – net of Discounts and Rebates | $ 207,898 | $ 100,932 | $ 369,990 | $ 264,484 | ||||
| Cost of Revenues | 151,100 | 50,051 | 236,815 | 123,323 | ||||
| Gross Profit | 56,798 | 50,881 | 133,175 | 141,161 | ||||
| Research Revenues | 206,939 | 299,670 | ||||||
| Net Revenue | 56,798 | 257,820 | 133,175 | 440,831 | ||||
| Operating Expenses: | ||||||||
| Research and Development | 598,653 | 231,912 | 880,117 | 602,725 | ||||
| General and Administrative Expenses | 1,729,247 | 1,632,236 | 3,619,121 | 3,355,372 | ||||
| Total Operating Expenses | 2,327,900 | 1,864,148 | 4,499,238 | 3,958,097 | ||||
| Loss from Operations | (2,271,102) | (1,606,328) | (4,366,063) | (3,517,266) | ||||
| Interest Expense | (1,403) | (1,221) | (2,792) | (3,011) | ||||
| Change in Fair Value of Derivative Liabilities | (5,665) | (140,447) | (10,232) | (135,342) | ||||
| Other Income, net | 12,584 | 13,066 | 23,346 | 43,388 | ||||
| Total Interest and Other Income (Loss), net | 5,516 | (128,602) | 10,322 | (94,965) | ||||
| Loss from Operations before Provision for Income Taxes | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Provision for Income Taxes (Note 10) | ||||||||
| Net Loss including Noncontrolling Interest | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Net Loss – Noncontrolling Interest | (1,060) | (1,204) | (2,001) | (1,956) | ||||
| Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (2,264,526) | (1,733,726) | (4,353,740) | (3,610,275) | ||||
| Comprehensive Loss: | ||||||||
| Net Loss | (2,265,586) | (1,734,930) | (4,355,741) | (3,612,231) | ||||
| Unrealized Foreign Currency Translation Gain | 2,552 | 17,242 | 8,494 | 7,338 | ||||
| Total Comprehensive Loss | (2,263,034) | (1,717,688) | (4,347,247) | (3,604,893) | ||||
| Net Loss – Noncontrolling Interest | (1,060) | (1,204) | (2,001) | (1,956) | ||||
| Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc. | (2,261,974) | (1,716,484) | (4,345,246) | (3,602,937) | ||||
| Cumulative Dividends on Series A Preferred Stock | (134,307) | (126,705) | (259,619) | (244,863) | ||||
| Net Loss - attributed to common stockholders | $ (2,396,281) | $ (1,843,189) | $ (4,604,865) | $ (3,847,800) | ||||
| Net Loss per Common Share: | ||||||||
| Basic (in Dollars per share) | [1] | $ (0.9) | $ (5.01) | $ (2.1) | $ (11.16) | |||
| Diluted (in Dollars per share) | $ (0.9) | [1] | $ (5.01) | [1] | $ (2.1) | $ (11.16) | ||
| Weighted Average Number of Common Shares Outstanding | ||||||||
| Basic (in Shares) | [1] | 2,653,848 | 368,250 | 2,192,367 | 344,701 | |||
| Diluted (in Shares) | 2,653,848 | [1] | 368,250 | [1] | 2,192,367 | 344,701 | ||
| ||||||||